Skip to main content

Advertisement

SpringerLink
Log in

Hip fracture and other predictors of anti-osteoporosis drug use in Norway

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Summary

This study aims to find predictors of anti-osteoporosis drug (AOD) use. Known risk factors of osteoporosis, i.e., age, hip fracture, and corticosteroid use were found to be predictors of AOD use, in addition to a number of other drugs used. Higher socioeconomic position did not favor the use of AOD.

Introduction

This study deals with studying predictors of anti-osteoporosis drug treatment in Norwegian women and men.

Methods

All Norwegian women and men ≥50 years were included (n = 1,407,392). Data were taken from different data sources, (1) the Norwegian Prescription Database (drug use in 2004–2005); (2) the Nationwide Census 2001 (marital status, education and resident county); (3) the National Hip Fracture Database (hip fractures 2003–2005); and (4) the National Population Register (date of death/emigration). We estimated the hazard ratios (HR) for incident treatment by Cox proportional hazard regression.

Results

In 2005, 10,332 women (1.5 %) and 1,387 men (0.2 %) were new users of anti-osteoporosis drugs (incident treatment). Age was a statistically significant predictor of incident treatment in both women and men, with HR ranging from 1.7 to 3.2 (per 10 years). A middle educational level in men strongly predicted incident treatment [HR 2.0 (CI 1.1–3.8)], but not in women after full adjustment. A previous hip fracture, increasing number of drugs used and use of corticosteroids were all predictors of incident treatment in both genders after adjustments. Corticosteroid use [HRwomen = 4.0 (CI 3.8–4.2)] had a higher HR for incident treatment than hip fracture [HRwomen = 2.0 (CI 1.8–2.3)]. Marital status and area of residency were not predictors of incident treatment in either gender, after adjustments. The predictors of prevalent treatment were only slightly different from incident treatment in 2005.

Conclusions

Age, previous hip fracture, number of drugs used, and use of corticosteroids were positively related to treatment in both genders. In men, a middle educational level predicted treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Falch JA, Meyer HE (1998) Osteoporosis and fractures in Norway. Occurrence and risk factors. Tidsskr Nor Laegeforen 118:568–572

    PubMed  CAS  Google Scholar 

  2. Lofthus CM, Osnes EK, Falch JA, Kaastad TS, Kristiansen IS, Nordsletten L, Stensvold I, Meyer HE (2001) Epidemiology of hip fractures in Oslo, Norway. Bone 29:413–418

    Article  PubMed  CAS  Google Scholar 

  3. Lunt M, Felsenberg D, Adams J, Benevolenskaya L, Cannata J, Dequeker J, Dodenhof C, Falch JA, Johnell O, Khaw KT, Masaryk P, Pols H, Poor G, Reid D, Scheidt-Nave C, Weber K, Silman AJ, Reeve J (1997) Population-based geographic variations in DXA bone density in Europe: the EVOS Study. European Vertebral Osteoporosis. Osteoporos Int 7:175–189

    Article  PubMed  CAS  Google Scholar 

  4. O’Neill TW, Felsenberg D, Varlow J, Cooper C, Kanis JA, Silman AJ (1996) The prevalence of vertebral deformity in European men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res 11:1010–1018

    Article  PubMed  Google Scholar 

  5. Boonen S, Autier P, Barette M, Vanderschueren D, Lips P, Haentjens P (2004) Functional outcome and quality of life following hip fracture in elderly women: a prospective controlled study. Osteoporos Int 15:87–94

    Article  PubMed  Google Scholar 

  6. Cooper C (1997) The crippling consequences of fractures and their impact on quality of life. Am J Med 103:12S–17S

    Article  PubMed  CAS  Google Scholar 

  7. Forsen L, Sogaard AJ, Meyer HE, Edna T, Kopjar B (1999) Survival after hip fracture: short- and long-term excess mortality according to age and gender. Osteoporos Int 10:73–78

    Article  PubMed  CAS  Google Scholar 

  8. Johnell O, Kanis JA, Jonsson B, Oden A, Johansson H, De LC (2005) The burden of hospitalised fractures in Sweden. Osteoporos Int 16:222–228

    Article  PubMed  CAS  Google Scholar 

  9. Osnes EK, Lofthus CM, Meyer HE, Falch JA, Nordsletten L, Cappelen I, Kristiansen IS (2004) Consequences of hip fracture on activities of daily life and residential needs. Osteoporos Int 15:567–574

    Article  PubMed  CAS  Google Scholar 

  10. Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726–1733

    Article  PubMed  CAS  Google Scholar 

  11. Bliuc D, Ong CR, Eisman JA, Center JR (2005) Barriers to effective management of osteoporosis in moderate and minimal trauma fractures: a prospective study. Osteoporos Int 16:977–982

    Article  PubMed  Google Scholar 

  12. Eisman J, Clapham S, Kehoe L, Australian BS (2004) Osteoporosis prevalence and levels of treatment in primary care: the Australian BoneCare Study. J Bone Miner Res 19:1969–1975

    Article  PubMed  Google Scholar 

  13. Colon-Emeric C, Lyles KW, Levine DA, House P, Schenck A, Gorospe J, Fermazin M, Oliver K, Alison J, Weisman N, Xie A, Curtis JR, Saag K (2007) Prevalence and predictors of osteoporosis treatment in nursing home residents with known osteoporosis or recent fracture. Osteoporos Int 18:553–559

    Article  PubMed  CAS  Google Scholar 

  14. Luthje P, Nurmi-Luthje I, Kaukonen JP, Kuurne S, Naboulsi H, Kataja M (2009) Undertreatment of osteoporosis following hip fracture in the elderly. Arch Gerontol Geriatr 49:153–157

    Article  PubMed  Google Scholar 

  15. Panneman MJ, Lips P, Sen SS, Herings RM (2004) Undertreatment with anti-osteoporotic drugs after hospitalization for fracture. Osteoporos Int 15:120–124

    Article  PubMed  Google Scholar 

  16. Solomon DH, Morris C, Cheng H, Cabral D, Katz JN, Finkelstein JS, Avorn J (2005) Medication use patterns for osteoporosis: an assessment of guidelines, treatment rates, and quality improvement interventions. Mayo Clin Proc 80:194–202

    Article  PubMed  Google Scholar 

  17. Devold HM, Doung GM, Tverdal A, Furu K, Meyer HE, Falch JA, Sogaard AJ (2010) Prescription of anti-osteoporosis drugs during 2004–2007—a nationwide register study in Norway. Eur J Clin Pharmacol 66:299–306

    Article  PubMed  Google Scholar 

  18. Sosial- og helsedirektoratet (2005) Faglige retningslinjer for forebygging og behandling av osteoporose og osteoporotiske brudd. Sosial-og helsedirektoratet, Oslo

    Google Scholar 

  19. Asche C, Nelson R, McAdam-Marx C, Jhaveri M, Ye X (2010) Predictors of oral bisphosphonate prescriptions in post-menopausal women with osteoporosis in a real-world setting in the USA. Osteoporos Int 21:1427–1436

    Article  PubMed  CAS  Google Scholar 

  20. Cranney A, Tsang JF, Leslie WD (2009) Factors predicting osteoporosis treatment initiation in a regionally based cohort. Osteoporos Int 20:1621–1625

    Article  PubMed  CAS  Google Scholar 

  21. Onder G, Pedone C, Gambassi G, Landi F, Cesari M, Bernabei R (2001) Treatment of osteoporosis among older adults discharged from hospital in Italy. Eur J Clin Pharmacol 57:599–604

    Article  PubMed  CAS  Google Scholar 

  22. Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, Sorensen HT (2010) The Nordic countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol 106:86–94

    Article  PubMed  CAS  Google Scholar 

  23. WHO Collaborating Centre for Drug Statistics Methodology (2009) Guildelines for ATC classification and DDD assignment 2009. Norwegian Institute of Public Health, Oslo

    Google Scholar 

  24. NOREPOS—The Norwegian Epidemiologic Osteoporosis Studies. www.norepos.no. Accessed 16 Aug 2011

  25. Statistics Norway. Population and housing census 2001. http://www.ssb.no/fob_en/. Accessed 22 Sept 2009

  26. The Norwegian prescription database. http://www.norpd.no/. Accessed 1 Nov 2009

  27. Statistics Norway. Education register. http://www.ssb.no/english/subjects/04/01/utniv_en/. Accessed 25 Aug 2009

  28. Statistics Norway. StatBank Norway. http://statbank.ssb.no/statistikkbanken/. Accessed 6 Sept 2011

  29. Roerholt C, Eiken P, Abrahamsen B (2009) Initiation of anti-osteoporotic therapy in patients with recent fractures: a nationwide analysis of prescription rates and persistence. Osteoporos Int 20:299–307

    Article  PubMed  CAS  Google Scholar 

  30. Cadarette SM, Katz JN, Brookhart MA, Levin R, Stedman MR, Choudhry NK, Solomon DH (2008) Trends in drug prescribing for osteoporosis after hip fracture, 1995–2004. J Rheumatol 35:319–326

    PubMed  Google Scholar 

  31. Beaupre LA, Morrish DW, Hanley DA, Maksymowych WP, Bell NR, Juby AG, Majumdar SR (2011) Oral bisphosphonates are associated with reduced mortality after hip fracture. Osteoporos Int 22:983–991

    Article  PubMed  CAS  Google Scholar 

  32. Maggi S, Siviero P, Gonnelli S, Caffarelli C, Gandolini G, Cisari C, Rossini M, Iolascon G, Mauro GL, Nuti R, Crepaldi G (2011) The burden of previous fractures in hip fracture patients. The Break Study. Aging Clin Exp Res 23:183–186

    PubMed  Google Scholar 

  33. McLellan AR, Wolowacz SE, Zimovetz EA, Beard SM, Lock S, McCrink L, Adekunle F, Roberts D (2011) Fracture liaison services for the evaluation and management of patients with osteoporotic fracture: a cost-effectiveness evaluation based on data collected over 8 years of service provision. Osteoporos Int 22:2083–2098

    Article  PubMed  CAS  Google Scholar 

  34. Compston J, Cooper A, Cooper C, Francis R, Kanis JA, Reid DM, Selby P, Wilkins M (2010) Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men of 50 years in the UK. National Osteoporosis Guideline Group (NOGG)

  35. Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F, Rizzoli R (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19:399–428

    Article  PubMed  CAS  Google Scholar 

  36. Varenna M, Binelli L, Zucchi F, Ghiringhelli D, Gallazzi M, Sinigaglia L (1999) Prevalence of osteoporosis by educational level in a cohort of postmenopausal women. Osteoporos Int 9:236–241

    Article  PubMed  CAS  Google Scholar 

  37. Cadarette SM, Gignac MA, Jaglal SB, Beaton DE, Hawker GA (2007) Access to osteoporosis treatment is critically linked to access to dual-energy X-ray absorptiometry testing. Med Care 45:896–901

    Article  PubMed  Google Scholar 

  38. Brask-Lindemann D, Cadarette SM, Eskildsen P, Abrahamsen B (2011) Osteoporosis pharmacotherapy following bone densitometry: importance of patient beliefs and understanding of DXA results. Osteoporos Int 22:1493–1501

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We would like to thank Electrical Engineer and System Architect Tomislav Dimoski at the Norwegian Knowledge Centre for the Health Services who developed the system which enabled extraction and transfer of data from the hospital’s patient administrative systems. He and his team also carried through the collection of the hip fracture data. The staffs at the Department of Pharmacoepidemiology, the Norwegian Institute of Public Health (NIPH) and our collaborators at Statistics Norway deserve appreciation for assisting in transferring the hip fracture data to the NIPH and in the encryption process. Thanks are also given to post doc Kristin Holvik, post doc Tone M. Omsland and senior advisor Dominic A. Hoff at the NIPH for their thorough and substantial task with quality control of the hip fracture data.

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway

    H. M. Devold, A. J. Søgaard, J. A. Falch & H. E. Meyer

  2. Department of Pharmacoepidemiology, Norwegian Institute of Public Health, Oslo, Norway

    A. Tverdal & K. Furu

  3. Pharmacy, University of Tromsø, Tromsø, Norway

    K. Furu

  4. Institute of General Practice and Community Medicine, University of Oslo, Oslo, Norway

    H. E. Meyer

Authors
  1. H. M. Devold
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. J. Søgaard
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Tverdal
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. A. Falch
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K. Furu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H. E. Meyer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H. M. Devold.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Devold, H.M., Søgaard, A.J., Tverdal, A. et al. Hip fracture and other predictors of anti-osteoporosis drug use in Norway. Osteoporos Int 24, 1225–1233 (2013). https://doi.org/10.1007/s00198-012-2063-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-012-2063-1

Keywords

Search

Navigation